showing Ͼ80% inhibition at 8 mg/mL. AHCC also decreased the levels of iNOS protein and mRNA. However, AHCC influenced neither the degradation of inhibitory protein B (IB) nor the activation of NFB stimulated by IL-1␤. Transfection experiments with an iNOS promoter-luciferase construct (iNOS-Luc) revealed that AHCC had no effect on the transactivation activity of the iNOS promoter. By contrast, AHCC inhibited the activity of iNOS-Luc containing a 3Јuntrans-lated region (UTR) with adenosine and uridine (AU)-rich elements, which shows the stabilizing activity of iNOS mRNA. Conclusions: Results indicated that AHCC inhibits the induction of iNOS at the level of transcription, causing a decrease in NO production in hepatocytes. AHCC seems to decrease the levels of iNOS mRNA by reducing mRNA stabilization rather than inhibiting its synthesis. Nitric oxide (NO), a short-lived free radical, mediates a variety of physiologic functions, including vascular tone regulation, neurotransmission, and immune response mediation. 1 In the liver, NO is generated from D-arginine by constitutively expressed endothelial nitric oxide synthase (eNOS) or inducible nitric oxide synthase (iNOS). eNOS is located in vascular endothelial cells and plays important roles in microvascular homeostasis. By contrast, iNOS is not present under physiologic conditions but is induced transcriptionally under pathologic conditions such as endotoxin shock, warm ischemia-reperfusion, hepatitis, and liver cirrhosis. In liver injury, lipopolysaccharide and proinflammatory cytokines such as tumor necrosis factor (TNF)-␣ and interleukin (IL)-1␤ stimulate the induction of iNOS gene expression, which is followed by excess production of NO. A relatively large amount of NO production influences metabolism and various hepatic functions.
NO has cytoprotective effects in the liver during endotoxemia and other types of fulminant hepatic failure [2] [3] [4] and is a potent antimalarial effector molecule in hepatocytes. 5 By contrast, Thiemerman et al 6 found that an iNOS-selective inhibitor attenuated liver damage and dysfunction in lipopolysaccharide-treated rats. NO inhibits Krebs cycle enzymes in the mitochondria within hepatocytes, 7 resulting in a decrease in hepatic ATP levels in rat models of partial hepatectomy, 8 obstructive jaundice, 9 and sepsis. 10 Thus, the production of NO is implicated in diverse functions associated with cytoprotection or injury in the liver.
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Whether NO protects or injures probably depends on the type of insult, the source and amount of NO production, and the cellular redox status of the liver. 12 Active hexose correlated compound (AHCC), which is extracted from mushrooms (Basidiomycetes), was developed by the Amino Up Chemical Co Ltd (Sapporo, Japan) in 1989. AHCC is a "complex compound" containing a variety of polysaccharides and other components, in which acetylated ␣-1,4 glucan is one of the major components. The application of AHCC has been rapidly increased in complementary and alternative medicine as a functional food. 13, 14 In clinical studies, AHCC has been reported to improve the prognosis of postoperative hepatocellular carcinoma patients.
Furthermore, it was reported that AHCC protects the liver from carbon tetrachloride (CCl 4 )-induced liver damage in mice. 16 However, the molecular mechanism by which AHCC protects the liver is not fully understood.
In this study, the possibility of AHCC regulation of NO production by IL-1␤-stimulated iNOS was pursued as a possible liver-protecting mechanism. We examined whether AHCC influences the induction of iNOS stimulated by proinflammatory cytokines in primary cultures of rat hepatocytes.
MATERIALS AND METHODS

Materials
Recombinant human IL-1␤ (2 ϫ 10 7 units/mg protein) was provided by Otsuka Pharmaceutical Co (Tokushima, Japan). [␥-
32 P]Adenosine-5Ј-triphosphate (ATP, Ϫ222 TBq/mmol) and [␣-
32 P]deoxycytidine-5Ј-triphosphate (dCTP, Ϫ111 TBq/mmol) were from DuPont-New England Nuclear Japan (Tokyo, Japan). AHCC was provided by the Amino Up Chemical Co Ltd and dissolved in Williams' medium E. All other chemicals were of reagent grade. Rats were kept at 22°C under a 12-hour light-dark cycle and received food and water ad libitum. Animal experiments were approved by the Animal Care Committee of Kansai Medical University.
Primary Cultures of Hepatocytes
Hepatocytes were isolated from male Wistar-strain rats (200 -250 g; Charles River, Boston, MA) by collagenase (Wako Pure Chemical, Osaka, Japan) perfusion, as described previously. 17 The isolated hepatocytes were suspended in culture medium at 6 ϫ 10 5 cells/mL, seeded into plastic dishes (2 mL/35 mm; Falcon Plastic, Oxnard, CA), and cultured at 37°C in a CO 2 incubator under a humidified atmosphere of 5% CO 2 in air. The culture medium was Williams' medium E supplemented with 10% newborn calf serum, Hepes (5 mmol/L), penicillin (100 units/mL), streptomycin (0.1 mg/mL), dexamethasone (10 nmol/L), and insulin (10 nmol/L). After 7 hours, the medium was replaced with fresh serum-and hormone-free medium; cells were cultured overnight and used in experiments. The purity of isolated hepatocytes was Ͼ99% by microscopic observation. 18 The number of cells attached to the dishes was calculated by counting the nuclei 19 and using a ratio of 1.37 Ϯ 0.04 nuclei per cell (mean Ϯ SE; n ϭ 7 independent experiments).
Treatment of Cells With AHCC
On day 1, cultured hepatocytes were washed with fresh serum-and hormone-free medium, treated with AHCC at various concentrations (1-8 mg/mL) 30 minutes before experiments, and then incubated with IL-1␤ (1 nmol/L) in the same medium for the indicated times.
Determinations of NO Production and Lactate Dehydrogenase (LDH)
Culture medium was used for the measurements of nitrite (a stable metabolite of NO) as an indicator of the level of NO by the method of Griess, 20 and LDH activity for a measure of cellular viability using a commercial kit (Wako Pure Chemical).
Western Blot Analysis
Cells (1 ϫ 10 6 cells/dish, 35 ϫ 10 mm) were lysed in 100 -200 L of solubilizing buffer (10 mmol/L Tris-HCl, pH 7.4, containing 1% Triton X-100, 0.5% Nonidet P-40, 1 mmol/L sodium orthovanadate, 1 mmol/L phenylmethylsulfonylfluoride [PMSF] , and a protease inhibitor cocktail; Roche Diagnostics, Mannheim, Germany), passed through a 26-gauge needle, and incubated on ice for 30 minutes, followed by centrifugation (16,000 ϫ g for 15 minutes). The supernatant (total cell lysate) was mixed with sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) sample buffer (final concentrations: 125 mmol/L Tris-HCl buffer, pH 6.8, containing 5% glycerol, 2% SDS, and 1% 2-mercaptoethanol), subjected to SDS-PAGE and electroblotted onto a polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA). Immunostaining was performed using a rabbit polyclonal antibody directed against mouse iNOS (Affinity BioReagents, Golden, CO) as the primary antibody and an enhanced chemiluminescence (ECL) blotting detection reagent (GE Healthcare Biosciences Corp, NJ).
Northern Blot Analysis
Total RNA was extracted from cultured hepatocytes using the acid guanidinium-phenol-chloroform method. 21 Total RNA (10 g) was fractionated by 1% agarose-formaldehyde gel electrophoresis, transferred to nylon membranes (Nytran; Schleicher & Schuell, Dassel, Germany), and immobilized by baking at 80°C for 1 hour before hybridization with DNA probes. A cDNA probe for rat iNOS (830 base pairs) was provided. 22 A cDNA encoding mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 23 was prepared by polymerase chain reaction (PCR). 24 These cDNAs were radiolabeled with [␣-32 P]dCTP by the random priming method.
Electrophoretic Mobility Shift Assay (EMSA)
Nuclear extracts were prepared at 4°C according to the method of Schreiber et al, 25 with minor modifications, 26 unless otherwise stated. Briefly, approximately 2 ϫ 10 6 cells (2 35-mm dishes) were placed on ice, washed with Tris-buffered saline, harvested in the same buffer, and centrifuged (1840 ϫ g for 1 minute). Cell pellets were resuspended in 400 L of lysis buffer (10 mmol/L Hepes, pH 7.9, 10 mmol/L KCl, 0.1 mmol/L EDTA, 0.1 mmol/L EGTA, 500 U/mL aprotinin, 0.5 mmol/L PMSF, and 1 mmol/L dithiothreitol), and cells were allowed to swell on ice for 15 minutes. Twentyfive microliters of 10% Nonident P-40 was added to the lysis buffer and the tube was vigorously vortexed for 1 minute at room temperature and then centrifuged 374 MATSUI ET AL Vol. 31, No. 5 (15,000 ϫ g for 1 minute). After removal of the supernatant, the nuclear pellet was resuspended in 75 L of nuclear extraction buffer (20 mmol/L Hepes, pH 7.9, 0.4 M NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 500 U/mL aprotinin, 1 mmol/L PMSF, and 1 mmol/L dithiothreitol). The tube was incubated on ice for 20 minutes with continuous mixing and then centrifuged (15,000 ϫ g for 5 minutes). Aliquots of the supernatant were frozen with liquid nitrogen and stored at Ϫ80°C until use.
Binding reactions (15 L total) were performed by incubating an amount of nuclear extract containing 4 g of protein with reaction buffer (20 mmol/L Hepes, pH 7.9, 1 mmol/L EDTA, 60 mmol/L KCl, 10% glycerol, 1 mg of poly (dI-dC)) in the absence or presence of anti-p50 and anti-p65 antibodies (against nuclear factor B [NFB] p50 [NLS] and NFBp65 [H286]; Santa Cruz Biotech, Santa Cruz, CA) or cold probe as a competitor (250-fold excess), for 30 minutes, followed by a 20-minute incubation at room temperature with the probe (approximately 40,000 cpm). Products were electrophoresed at 100 V on a 4.8% polyacrylamide gel in high-ionic-strength buffer (50 mmol/L Tris-HCl, 380 mmol/L glycine, 2 mmol/L EDTA, pH 8.5), and dried gels were analyzed by autoradiography. An NF B consensus oligonucleotide (5Ј-AGTTGAGGGGA-CTT-TCCCAGGC) from mouse immunoglobulin k light chain was purchased (Promega, Madison, WI) and labeled with [␥-32 P]ATP using T4 polynucleotide kinase. The protein concentration was measured by the method of Bradford 27 with a dye-binding assay kit (Bio-Rad Laboratories), using bovine serum albumin as a standard.
Construction of Luciferase (Luc) Reporter Plasmids and Expression Plasmids
The 1.2-kb 5Ј-flanking region of the rat iNOS gene (deposited to the DDBJ/EMBL/GenBank under accession No. AB290142), including a TATA box, was inserted into pGL3-Basic vector (Promega) to create pRiNOS-Luc. 26 Rat cDNA for the 3Јuntranslated region (UTR) of iNOS mRNA was amplified using specific primers (5Ј-tgctctaGACAGTGAGGGGTTTG-GAGAGA-3Ј and 5Ј-gcggatcctttaTTCTTGATCAAACA-CTCATTTT-3Ј), and the resultant cDNA was digested with BamH I and Xba I. This cDNA for the iNOS 3ЈUTR (deposited under accession No. AB250951) replaced the SV40 polyadenylation signal of pRiNOSLuc to create pRiNOS-Luc-3ЈUTR.
Transfection and Luc Assay
Transfection of cultured hepatocytes was performed according to published methods. 26, 28 Briefly, hepatocytes were cultured at 4 ϫ 10 5 cells per dish (35 ϫ 10 mm) in Williams' medium E supplemented with serum, dexamethasone, and insulin for 7 hours. Then, cells were subjected to magnet-assisted transfection (MATra). Reporter plasmid pRiNOS-Luc or pRiNOSLuc-3ЈUTR (1 g) and cytomegalovirus (CMV) promot- 
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er-driven ␤-galactosidase plasmid pCMV-LacZ (1 ng) as an internal control were mixed with MATra-A reagent (1 L; IBA GmbH, Göttingen, Germany). After a 15-minute incubation on a magnetic plate at room temperature, the medium was replaced by fresh medium with serum. Then, cells were cultured overnight, treated with or without IL-1␤, and the Luc and ␤-galactosidase activities of the cell extracts were measured using PicaGene (Wako Pure Chemical) and ␤-Glo kits (Promega), respectively.
Statistical Analysis
Results in the figures are representative of 2-4 independent experiments yielding similar findings. Differences were analyzed by the Bonferroni/Dunn test, and p Ͻ .05 was considered to indicate statistical significance.
RESULTS
AHCC Decreases the Levels of NO Production in Hepatocytes
The proinflammatory cytokine IL-1␤ induced the gene expression of iNOS and increased the production 
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Vol. 31, No. 5 of NO in primary cultures of rat hepatocytes, as reported previously. 29, 30 Pretreatment of rat hepatocytes with AHCC inhibited NO production in a timedependent fashion ( Figure 1A) . Figure 1B shows the concentration dependence of the effect of AHCC in the presence of IL-1␤ for 8 hours. AHCC decreased the level of NO production in a dose-dependent manner to the maximum concentration tested, showing approximately 80% inhibition at a concentration of 8 mg/mL. AHCC (8 -10 mg/mL) alone had little effect on the production of NO. AHCC was not toxic to cells within the incubation periods, irrespective of the presence of IL-1␤, as tested by the release of LDH (Figure 2 ) and trypan blue exclusion (data not shown).
AHCC Inhibits the Induction of iNOS Protein and mRNA
We further investigated the mechanisms of the AHCC effect on NO production. Western blot analysis revealed that pretreatment of cells with AHCC decreased the levels of iNOS protein (130 kDa) both time and dose-dependently compared with IL-1␤ alone ( Figure 3A and B) . The level of iNOS mRNA was also decreased time-dependently in the presence of AHCC (Figure 4) .
AHCC Has No Effect on the Activation of NFB and the Degradation of Inhibitory Protein B (IB)
The promoters of the murine and human genes encoding iNOS contain a consensus sequence for the binding of the transcription factor NFB, [31] [32] [33] which is necessary to confer inducibility by cytokines. NFB is typically found in the form of a p50/p65 heterodimer attached to the inhibitory molecule IB in the cytoplasm of cells. 34 IL-1␤ stimulates the degradation of IB proteins, followed by the activation of NFB, that is, its nuclear translocation and DNA binding. An EMSA revealed that AHCC had no effect on NFB activation ( Figure 5A ). The supershift assays with antibodies against the NFB subunits p50 and p65 revealed that AHCC also had no effect on the component subunits of NFB ( Figure 5B ). Furthermore, Western blot analysis of IB proteins showed that AHCC had no effect on the degradation of IB␣ and IB␤ stimulated by IL-1␤ ( Figure 6 ). These results suggested that AHCC had no significant effect on the translocation of NFB from the cytoplasm to the nucleus or on its DNA binding.
AHCC Inhibits the Activity of the iNOS Promoter Construct Containing 3ЈUTR
In transfection experiments, we used 2 iNOS promoter firefly Luc constructs: pRiNOS-Luc and pRiNOS-Luc-3ЈUTR ( Figure 7A ). The former harbored the 1.2-kb promoter of the rat iNOS gene, the Luc gene and an SV40 polyadenylation signal (SVpA). The SVpA has no AU-rich element (ARE) and is known to stabilize mRNA. The latter harbored the 3ЈUTR of the rat iNOS mRNA, downstream of the Luc gene, instead of the SVpA. The rat iNOS 3ЈUTR contains 6 AREs (5Ј-AUUUA-3Ј or 5Ј-AUUUUA-3Ј), which are usually found in unstable mammalian mRNAs encoding acute phase proteins and cytokines and are involved in the stabilization of mRNA. 35, 36 When the iNOS promoterLuc-SVpA construct (pRiNOS-Luc-SVpA) was introduced into hepatocytes, IL-1␤ increased Luc activity with time, showing a maximal effect (6-to 8-fold of control) at 8 hours (data not shown). AHCC had no effect on the transactivation of the pRiNOS-Luc pro- Figure 7B ). When the iNOS promoterLuc-3ЈUTR construct (pRiNOS-Luc-3ЈUTR)-which responded to IL-1␤ faster than pRiNOS-Luc did-was introduced into heptocytes, a maximal effect (4-to 6-fold of control) was seen at 3 hours; however, AHCC significantly inhibited the activity of the pRiNOS-Luc-3ЈUTR promoter ( Figure 7C ). These results suggested that AHCC inhibited the stabilization of iNOS mRNA.
DISCUSSION
In the present study, we found that AHCC markedly inhibited the induction of iNOS mRNA and protein (Figures 3 and 4) and NO production ( Figure 1 ) stimulated by the proinflammatory cytokine IL-1␤ in primary cultures of rat hepatocytes. AHCC could not influence the IB/NFB pathway, which is stimulated by IL-1␤ through the activation of IB kinase, as it had no effect on the degradation of the IB proteins IB␣ and IB␤ (Figure 6 ) or on the activation of NFB (its nuclear translocation and DNA binding; Figure 5 ). This suggests that the transcriptional activation of the iNOS gene by the transcription factor NFB remains unchanged.
In support of these observations, transfection experiments with an iNOS promoter-luciferase construct (pRiNOS-Luc), which detects the transcriptional activity of iNOS mRNA (synthesis of mRNA), showed that AHCC had no inhibitory effect ( Figure 7B ). By contrast, experiments with an iNOS promoter construct containing its 3ЈUTR (pRiNOS-Luc-3ЈUTR) revealed that AHCC significantly reduced Luc activity ( Figure  7C ), suggesting that the 3ЈUTR of iNOS mRNA is involved in its stability. These results indicate that AHCC presumably destabilizes iNOS mRNA at a posttranscriptional step, as shown in Figure 8 .
Recent accumulated evidence suggests that posttranscriptional mechanisms such as mRNA stabilization are critically involved in the regulation of iNOS expression. 35, 36 The 3ЈUTR of iNOS mRNA, which contains 6 AREs (AUUU(U)A), is associated with AREbinding proteins such as HuR and hnRNPI/L, resulting 
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It is possible that the inhibitory effect of AHCC on the production of NO through the inhibition of iNOS induction is associated with AHCC-induced protection against liver failure. Further investigation is needed to delineate the mechanism by which AHCC acts on iNOS expression in hepatocytes, as well as to perform an in vivo study with an animal model of liver injury. The fractionation and purification of the complex compound AHCC are also needed to identify the effective component associated with the inhibition of iNOS induction and the prevention of liver injury. Such studies may provide a foundation for novel pharmacologic approaches to prevent liver dysfunction.
Discussant
Arlet Kurkchubasche, MD Rhode Island Hospital 1. Conceptually, do the authors believe that this (inducible nitric oxide [iNOS] , NO reduction) is the clinically relevant mechanism? Did you postulate that reduction in iNOS would be protective in chemotherapy-induced hepatotoxity? There was little background discussion to support the experimental protocol. Or was this study done to evaluate whether this substance would be another effective iNOS inhibitor like L-NMME or L-NAME, according to its reported clinical performance? 2. Because the substance is thought to have multiple different potential effects on immune function, including enhanced NK activity, the question naturally arises whether the investigators' dosing would be considered analogous to the amounts recommended in clinical practice (dosing is about 1000 mg 3 times per day on the websites; eg, we often attribute different effects to differing doses of a "medication"). Is this at play here? 3. For protocol, my first question also related to the choice of dosing. Did you try logarithmic increases in dosing, or how did you determine that you would see dose dependence in the 0 -10 mg/mL range? It would be interesting to know whether you were able to inhibit IL-1␤-stimulated NO production completely at any dose. It would be interesting to see whether higher doses had effects on cell viability. 4. As the authors allude to, further experiments are essential. Certainly the next experiment might involve "injured" and "noninjured" animals treated with AHCC who then undergo hepatocyte isolation and are tested for responsiveness to IL-1␤ in terms of NO production. Do you have any preliminary data?
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